A Phase 3 interventional study of SGX301 (synthetic hypericin) and Placebo in Cutaneous T-Cell Lymphoma, sponsored by Soligenix. Completed at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-15.
Sponsored by Soligenix · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.
Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 17th largest by enrollment of the 279 interventional ones that give a count, is one of 6 that started in 2015, is one of 19 in phase 3, and was the 293rd registered.
447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.
Browse Mycosis Fungoides studies →24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:
Kyowa Kirin, Inc. · Sites in United States, Italy, Spain
Ages 18+
Prescient Therapeutics, Ltd. · Sites in United States, Australia, France and 1 more country
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
University of California, Irvine · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
360 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 164 · Phase 2 135 · Phase 3 20 · Phase 4 4
First in 1988; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 169 is above the median of 34 across 321 interventional studies indexed under Mycosis Fungoides.
Median enrollment 32 across the 279 interventional studies, 65 across the 34 observational. Of the 301 that completed or were terminated, 95 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 360 have an industry lead sponsor. The 10 most frequent:
Soligenix is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Soligenix has 4 studies filed under Mycosis Fungoides — fewer than ten, so there is no comparison to draw.
12 of the studies in Mycosis Fungoides with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04256018Stanford UniversityMogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | 2026-12 |
| NCT07003100City of Hope Medical CenterA Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | 2027-01-12 |
| NCT05357794M.D. Anderson Cancer CenterEffectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | 2027-01-30 |
| NCT05944562Washington University School of MedicineTulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome | 2027-02-28 |
| NCT05296304Memorial Sloan Kettering Cancer CenterA Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | 2027-03 |
Add all 12 to your calendar (.ics) → With an account.
Among the 360 studies in Mycosis Fungoides with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.
This study's enrollment of 169 is above the median of 34 across 321 interventional studies indexed under Mycosis Fungoides.
Browse Mycosis Fungoides studies →Soligenix is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Compared within Mycosis Fungoides, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, T-Cell, Cutaneous. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy. Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated. Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment. Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index).
Drug: SGX301 (synthetic hypericin)
Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.
Drug: Placebo
0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
Also known as: Hypericin, Synthetic Hypericin
USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving Placebo
The percentage of patients achieving a treatment response in each of the 2 treatment groups. A treatment response was defined as a ≥50% improvement in CAILS score at Week 8 when compared to the CAILS score at baseline. The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome. The overall CAILS score was calculated by adding the total score as described above for each of the 3 lesions. The overall CAILS score has a range of 0 to 111. A lower score means a better outcome.
Time frame: 8 weeks
Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Measured by the Composite Assessment of Index Lesion Disease Severity (CAILS) Score (Cycle 1 and 2 SGX301 vs Cycle 1 Placebo)
The percentage of patients achieving a treatment response at Week 16 that received SGX301 for both Cycle 1 and 2 compared to the response rate in patients that received Placebo in Cycle 1. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.
Time frame: 16 weeks
Number of Responders and Non-Responders With a Treatment Response of 3 Treated Lesions as Measured by the Composite Assessment of Index Lesion Disease Severity (CAILS) Score in Patients Who Received 3 Cycles of SGX301
The percentage of patients achieving a treatment response at Week 24 compared at Week 16 in SGX301 treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.
Time frame: 24 weeks
Patch Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)
The proportion of patch lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.
Time frame: 16 weeks
Plaque Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)
The proportion of plaque lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.
Time frame: 16 weeks
| Milestone | SGX301 | Placebo |
|---|---|---|
| Started | 118 | 51 |
| Randomized, not treated | 2 | 1 |
| Cycle 1 | 116 | 50 |
| Cycle 2 | 110 | 45 |
| Cycle 3 | 78 | 32 |
| Follow-up period | 98 | 39 |
| Completed | 83 | 32 |
| Not completed | 35 | 19 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lost to follow-up | 16 | 9 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Withdrawal by subject | 13 | 9 |
| Withdrew: Noncompliance with study procedures | 2 | 0 |
The percentage of patients achieving a treatment response in each of the 2 treatment groups. A treatment response was defined as a ≥50% improvement in CAILS score at Week 8 when compared to the CAILS score at baseline. The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome. The overall CAILS score was calculated by adding the total score as described above for each of the 3 lesions. The overall CAILS score has a range of 0 to 111. A lower score means a better outcome.
| Participants | SGX301 | Placebo |
|---|---|---|
| Responder | 19 | 2 |
| Non-responder | 97 | 48 |
The percentage of patients achieving a treatment response at Week 16 that received SGX301 for both Cycle 1 and 2 compared to the response rate in patients that received Placebo in Cycle 1. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.
| Participants | SGX301 (Cycle 1 & 2 = SGX301) | Placebo (Cycle 1) |
|---|---|---|
| Responder | 44 | 2 |
| Non-responder | 66 | 48 |
The percentage of patients achieving a treatment response at Week 24 compared at Week 16 in SGX301 treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.
| Participants | SGX301 (Cycle 1, 2 & 3 = SGX301) |
|---|---|
| Responder | 38 |
| Non-responder | 40 |
The proportion of patch lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.
| lesions with response | SGX301 (Cycle 1 & 2 = SGX301) | Placebo (Cycle 1) |
|---|---|---|
| Patch Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo) | 65 | 14 |
The proportion of plaque lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.
| lesions with response | SGX301 (Cycle 1 & 2 = SGX301) | Placebo (Cycle 1) |
|---|---|---|
| Plaque Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo) | 64 | 7 |
Collected over From the first dose of study drug (SGX301 or Placebo) until 1 month following the participant's last evaluation visit (Cycle 1 = 8 weeks, Cycle 2 = 16 weeks, Cycle 3 = 24 weeks). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cycle 1 - SGX301 | 0/116 (0%) | 1/116 (0.9%) | 56/116 (48.3%) |
| Cycle 1 - Placebo | 0/50 (0%) | 1/50 (2%) | 26/50 (52%) |
| Cycle 2 - SGX301 | 0/155 (0%) | 0/155 (0%) | 66/155 (42.6%) |
| Cycle 3 - SGX301 | 0/110 (0%) | 3/110 (2.7%) | 49/110 (44.5%) |
| Overall SGX301 | 0/161 (0%) | 4/161 (2.5%) | 108/161 (67.1%) |
| Event | Cycle 1 - SGX301 | Cycle 1 - Placebo | Cycle 2 - SGX301 | Cycle 3 - SGX301 | Overall SGX301 |
|---|---|---|---|---|---|
| AngioedemaSkin and subcutaneous tissue disorders | 0/116 | 1/50 | 0/155 | 0/110 | 0/161 |
| Gallbladder obstructionHepatobiliary disorders | 0/116 | 0/50 | 0/155 | 1/110 | 1/161 |
| CholecystitisHepatobiliary disorders | 0/116 | 0/50 | 0/155 | 1/110 | 1/161 |
| PneumoniaInfections and infestations | 0/116 | 0/50 | 0/155 | 1/110 | 1/161 |
| Gastritis alcoholicGastrointestinal disorders | 1/116 | 0/50 | 0/155 | 0/110 | 1/161 |
| Event | Cycle 1 - SGX301 | Cycle 1 - Placebo | Cycle 2 - SGX301 | Cycle 3 - SGX301 | Overall SGX301 |
|---|---|---|---|---|---|
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 9/116 | 1/50 | 5/155 | 5/110 | 17/161 |
| Application site painGeneral disorders | 8/116 | 2/50 | 5/155 | 6/110 | 16/161 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 6/116 | 2/50 | 4/155 | 5/110 | 14/161 |
| Upper respiratory tract infectionInfections and infestations | 8/116 | 4/50 | 2/155 | 2/110 | 12/161 |
| PruritusSkin and subcutaneous tissue disorders | 6/116 | 2/50 | 2/155 | 5/110 | 12/161 |
| Viral upper respiratory tract infectionInfections and infestations | 4/116 | 0/50 | 4/155 | 4/110 | 11/161 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 3/116 | 3/50 | 6/155 | 4/110 | 11/161 |
| HeadacheNervous system disorders | 5/116 | 3/50 | 5/155 | 2/110 | 10/161 |
| Application site pruritusGeneral disorders | 5/116 | 1/50 | 5/155 | 0/110 | 9/161 |
| Application site paraesthesiaGeneral disorders | 6/116 | 0/50 | 2/155 | 2/110 | 7/161 |
The baseline analysis population was defined as all participants that were treated with at least one dose of treatment (SGX301 or Placebo)
| Age, Continuous(years) | SGX301 | Placebo | Total |
|---|---|---|---|
| Mean | 57.9 ± 15.94 | 59.4 ± 16.26 | 58.4 ± 16.00 |
| Sex: Female, Male(Participants) | SGX301 | Placebo | Total |
|---|---|---|---|
| Female | 47 | 23 | 70 |
| Male | 69 | 27 | 96 |
| Ethnicity (NIH/OMB)(Participants) | SGX301 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 3 | 13 |
| Not Hispanic or Latino | 103 | 45 | 148 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race/Ethnicity, Customized(Participants) | SGX301 | Placebo | Total |
|---|---|---|---|
| White | 84 | 36 | 120 |
| Black or African American | 27 | 12 | 39 |
| Asian | 4 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Other | 0 | 2 | 2 |
| Unknown | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Jun 2020, 54 months.
Results were first posted in Apr 2022, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Soligenix